IMA401 Posts 20% Response Rate in 41 Solid-Tumor Patients as Phase 1 Sets 1-2 mg Dose
Updated
Updated · Nature.com · May 31
IMA401 Posts 20% Response Rate in 41 Solid-Tumor Patients as Phase 1 Sets 1-2 mg Dose
2 articles · Updated · Nature.com · May 31
In 41 efficacy-evaluable patients treated at the recommended 1-2 mg dose, IMA401 delivered a 20% objective response rate and 51% disease control across more than 15 advanced solid-tumor types.
Safety in 61 treated patients was described as manageable: the maximum tolerated dose was not reached, low-grade cytokine release syndrome occurred in 38%, and the recommended phase 2 dose was set at 1-2 mg every two weeks.
Five dose-limiting toxicities were seen, mainly neutropenia; no further DLTs occurred within the RP2D range when dexamethasone premedication was used, though one possibly treatment-related death was reported at 2.5 mg outside that range.
Head and neck cancer showed the largest signal at RP2D, with a 29% response rate in 14 patients and median response duration of 8.8 months; combination use with pembrolizumab showed similar tolerability and no additive toxicity.
The first-in-human trial supports further development of the MAGE-A4/A8-targeting TCR-based bispecific in HLA-A*02:01-positive solid tumors, where off-the-shelf T-cell engagers have had limited success.
As similar cancer therapies emerge, what makes this new drug a potential game-changer for solid tumors?
Is combining two targeted therapies the key to unlocking a more powerful cancer treatment?